Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate.

JCO precision oncology·2026
Same author

Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans.

JAMA network open·2026
Same author

Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis.

JAMA network open·2026
Same author

Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers.

International journal of cancer·2026
Same author

The biology of hypomorphic TP53 variants and implications for clinical management.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Phenotyping Prostate Cancer in a National Health System Using Large Language Models.

JCO clinical cancer informatics·2026

Related Experiment Video

Updated: Jul 14, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.2K

Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer.

Luca F Valle1,2,3, Jiannong Li4, Heena Desai5,6

  • 1Radiation Oncology Service, Veterans Affairs (VA) Greater Los Angeles Healthcare System, Los Angeles, California.

JAMA Network Open
|May 12, 2025
PubMed
Summary

Genomic alterations in metastatic prostate cancer (mPCa) vary by race. Next-generation sequencing (NGS) identified differences in key pathways between non-Hispanic Black and White veterans, highlighting the need for equitable precision oncology.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.7K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

993

Related Experiment Videos

Last Updated: Jul 14, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.2K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.7K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

993

Area of Science:

  • Genomic medicine
  • Prostate cancer research
  • Health equity

Background:

  • National guidelines advocate for next-generation sequencing (NGS) in metastatic prostate cancer (mPCa) to identify actionable alterations.
  • Non-Hispanic Black men are underrepresented in precision oncology research, limiting understanding of genomic differences.
  • Characterizing these differences is crucial for equitable treatment strategies.

Purpose of the Study:

  • To analyze the spectrum and frequency of alterations in prostate cancer-related genes and pathways.
  • To investigate associations between these alterations, race/ethnicity, and overall survival in US veterans.
  • To inform precision oncology approaches for diverse patient populations.

Main Methods:

  • Retrospective cohort study of 5015 US veterans with mPCa undergoing NGS testing.
  • Comparison of alteration frequencies between non-Hispanic Black and non-Hispanic White veterans.
  • Statistical adjustments for NGS analyte and clinicopathologic covariates; survival analysis.

Main Results:

  • While top altered genes were similar, frequencies varied by race/ethnicity.
  • Non-Hispanic Black veterans showed higher odds of alterations in SPOP and immunotherapy targets (e.g., MSI-high).
  • Lower odds of alterations were observed in the AKT/PI3K pathway, androgen receptor axis, and tumor suppressor genes in non-Hispanic Black veterans.
  • Alterations in tumor suppressor genes (e.g., TP53) were associated with shorter survival in both groups.

Conclusions:

  • Significant differences in genomic alteration frequencies exist between racial groups in mPCa.
  • Genomic testing utility is confirmed for identifying candidates for precision oncology, irrespective of race.
  • Addressing these disparities can contribute to more equitable outcomes in prostate cancer care.